TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8141223

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (hematinic group, n = 53)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Hematonic group
Number of subjects: 97
Study: 3222676

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 29794951

Group type: EXPERIMENTAL
Intervention: Veinlite PEDI
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 112
Study: 30005020

Group type: EXPERIMENTAL
Intervention: Oligonucleotide ligation assay (OLA)
Number of subjects: 492
Study: 28865713

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Reduction of depressive symptoms
Number of subjects: 181
Study: 26528167

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 23025273

Group type: EXPERIMENTAL
Intervention: Horse meat consumption (2 portions of 175 g/week)
Number of subjects: 52
Study: 21403548

Group type: EXPERIMENTAL
Intervention: Endoscopic transethmoidal approach (ETEA) combined with transconjunctival inferior fornix approach (TIFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Medial canthal incision (MCI) combined with TIFA
Number of subjects: 59
Study: 19694038

Group type: EXPERIMENTAL
Intervention: MDS-HC
Number of subjects: 311

Group type: COMPARATOR
Intervention: NASC
Number of subjects: 311
Study: 16802483

Group type: EXPERIMENTAL
Intervention: 1.5 ml/kg Hartmann's solution
Number of subjects: 160

Group type: COMPARATOR
Intervention: 15 ml/kg Hartmann's solution
Number of subjects: 160
Study: 15370356

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study: 10928461

Group type: EXPERIMENTAL
Intervention: 150 microg levonorgestrel + 30 microg ethinylestradiol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel + 30 microg ethinylestradiol
Number of subjects: 28

Group type: COMPARATOR
Intervention: desogestrel-containing OC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both OC types
Number of subjects: 28
Study: 9054840

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily for 4 weeks)
Number of subjects: 0
Study: 8416460

Group type: EXPERIMENTAL
Intervention: Hydration group (2 L of water)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (100 mL of water)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydration group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 3519058

Group type: EXPERIMENTAL
Intervention: Guar gum (20 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No guar gum
Number of subjects: 6
Study: 31005913

Group type: EXPERIMENTAL
Intervention: Antenatal prebiotic maternal supplementation (galacto-oligosaccharide/inulin)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 376
Study: 28116761

Group type: EXPERIMENTAL
Intervention: Daily 1-hour nap opportunity
Number of subjects: 57

Group type: COMPARATOR
Intervention: No nap (control group)
Number of subjects: 57
Study: 24843115

Group type: EXPERIMENTAL
Intervention: New curriculum
Number of subjects: 9
Study: 24112150

Group type: EXPERIMENTAL
Intervention: Quitting smokers after 4-week smoking cessation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 42

Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quitting smokers
Number of subjects: 42
Study: 21520194

Group type: EXPERIMENTAL
Intervention: Maintenance peginterferon treatment
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Patients with cirrhosis
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Patients with fibrosis
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: CTP score≥7
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1050
Study: 18637601

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bupivacaine (Control)
Number of subjects: 26
Study: 16567825

Group type: EXPERIMENTAL
Intervention: Daclizumab (anti-CD25)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 36
Study: 12592052

Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.15% ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle-placebo
Number of subjects: 0
Study: 10971309

Group type: EXPERIMENTAL
Intervention: Dofetilide 1000 microg, twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dofetilide 1500 microg, twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dofetilide 2500 microg, twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dofetilide 1000 microg, three times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dofetilide 1500 microg, three times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dofetilide 2500 microg, three times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dofetilide (all doses, both regimens)
Number of subjects: 25
Study: 8982131

Group type: EXPERIMENTAL
Intervention: poly‐L‐lactic acid screws
Number of subjects: 43

Group type: COMPARATOR
Intervention: titanium screws
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 1443810

Group type: EXPERIMENTAL
Intervention: Intubated patients (more than 24 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intubated patients (0.5 and 0.75 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intubated patients (0.25 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 6419955

Group type: EXPERIMENTAL
Intervention: Dothiepin (Prothiaden)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: COMPARATOR
Intervention: Soft biteguard
Number of subjects: 93
Study: 31228412

Group type: EXPERIMENTAL
Intervention: Executive function performance
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Memory performance
Number of subjects: 547
Study: 30573002

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 460
Study: 26936861

Group type: EXPERIMENTAL
Intervention: Very early mobilization following stroke (intervention)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2104
Study: 25223209

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.1% monotherapy (n = 23)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Bromfenac 0.1% and Betamethasone 0.1% combination therapy (n = 28)
Number of subjects: 51
Study: 22708977

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) in addition to unrestricted services (US)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Unrestricted services (US)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 74
Study: 19819311

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-Reiki
Number of subjects: 35
Study: 17679735

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 2
Study: 16222961

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 12358657

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 microg x kg(‐1))
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg x kg(‐1))
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 microg x kg(‐1)) plus Ketamine (0.5 mg x kg(‐1))
Number of subjects: 109
Study: 11385810

Group type: EXPERIMENTAL
Intervention: Novolizer (MDPI) at peak inhaled flow rates of 90 l/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Novolizer (MDPI) at peak inhaled flow rates of 60 l/min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Novolizer (MDPI) at peak inhaled flow rates of 45 l/min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler at peak inhaled flow rate of 60 l/min
Number of subjects: 13
Study: 9692447

Group type: EXPERIMENTAL
Intervention: Medtronic‐Hall prosthesis
Number of subjects: 418

Group type: COMPARATOR
Intervention: Edwards‐Duromedics prosthesis
Number of subjects: 418

Group type: COMPARATOR
Intervention: Björk‐Shiley prosthesis
Number of subjects: 418

Group type: COMPARATOR
Intervention: All prostheses
Number of subjects: 418
Study: 8166055

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 2614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2614
Study: 2451954

Group type: EXPERIMENTAL
Intervention: 1040 regimen (cisplatin 80 mg/m2, vincristine 1 mg, methotrexate 10 mg/m2 on days 1, 2, 3, and bleomycin 10 mg/m2 on days 1, 2, 3)
Number of subjects: 209

Group type: COMPARATOR
Intervention: CDDP regimen (cisplatin 80 mg/m2 alone)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 1040 regimen
Number of subjects: 209

Group type: COMPARATOR
Intervention: CDDP regimen
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 209
Study: 29536284

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Cognitive Behavioral Therapy (MI + CBT)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Attention-matched education control
Number of subjects: 210
Study: 28971607

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir 90/400 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: emtricitabine/rilpivirine/TAF 200/25/25 mg
Number of subjects: 42
Study: 26440643

Group type: EXPERIMENTAL
Intervention: 10 g polydextrose/d (PDX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0 g polydextrose/d (control)
Number of subjects: 50
Study: 23980734

Group type: EXPERIMENTAL
Intervention: Resveratrol and quercetin combination (RQ)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study: 21392762

Group type: EXPERIMENTAL
Intervention: 4mg dexamethasone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone
Number of subjects: 93

Group type: COMPARATOR
Intervention: 4mg ondansetron
Number of subjects: 93

Group type: COMPARATOR
Intervention: ondansetron
Number of subjects: 93
Study: 18199920

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus hydrochlorothiazide 25 mg
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus hydrochlorothiazide 25 mg
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1181
Study: 16775667

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632
Study: 12750250

Group type: EXPERIMENTAL
Intervention: High red meat diet (420 grams)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low meat diet (60 grams)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vegetable protein equivalent to high red meat diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 8-mg supplement of haem iron
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 35-mg ferrous iron
Number of subjects: 21
Study: 10893688

Group type: EXPERIMENTAL
Intervention: Patients with prevalent vertebral fractures (VFX)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Patients without prevalent vertebral fractures (VFX)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Increasing number of VFX
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Patients with a single VFX
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: NHP and EQ-5D scores
Number of subjects: 751
Study: 8815701

Group type: EXPERIMENTAL
Intervention: Combination therapy with two nucleosides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study: 1475040

Group type: EXPERIMENTAL
Intervention: 1750 mg of the DA antagonist alpha‐methyl‐p‐tyrosine (AMPT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg ethanol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31517759

Group type: EXPERIMENTAL
Intervention: Workplace personal-fitness management program (PP) led by physical therapist, individualized for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG) received a 90-minute group-fitness management course
Number of subjects: 60
Study: 30481808

Group type: EXPERIMENTAL
Intervention: Tear film breakup time (TBUT) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis based on symptoms and TBUT test
Number of subjects: 0
Study: 27400469

Group type: EXPERIMENTAL
Intervention: Decoction of Nicotiana tabacum leaves mouthwash (10 mL 3 times a day for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthwash (10 mL 3 times a day for 5 days)
Number of subjects: 60
Study: 25210961

Group type: EXPERIMENTAL
Intervention: Transcostal suture (TS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pericostal suture (PS)
Number of subjects: 30
Study: 22302182

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (supplementary coffee intake)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline MPI (caffeine-abstinent)
Number of subjects: 30
Study: 20590751

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 17645577

Group type: EXPERIMENTAL
Intervention: L-T3 (50 microg qd) for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 20
Study: 16236864

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 18 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (patients who could not tolerate CPAP)
Number of subjects: 95
Study: 12098564

Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN) 1b therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 10642067

Group type: EXPERIMENTAL
Intervention: Exercise-HBO2 (breathing 95% O2 at 2.5 atm abs for 90 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise-no HBO2
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise-HBO2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 8618852

Group type: EXPERIMENTAL
Intervention: Maternal plasma HIV-1 RNA levels at delivery (190,400-1,664,100 copies/ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maternal plasma HIV-1 RNA levels at delivery (500-155,800 copies/ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Viral RNA level < or = 100,000 copies/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serial HIV-1 RNA levels during pregnancy
Number of subjects: 30
Study: 2157829

Group type: EXPERIMENTAL
Intervention: Technetium-99m (99mTc) imaging
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Iodine-123 (123I) imaging
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Cytologic/histologic examination
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Overall quality of 123I scans
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Routine reimaging of 99mTc hot nodules with radioiodine
Number of subjects: 316
Study: 6104976

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rimiterol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Salbutamol and Rimiterol (equivalent molar amounts)
Number of subjects: 4
Study: 26689935

Group type: COMPARATOR
Intervention: Anodal stimulation on left DLPFC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cathodal stimulation on left DLPFC
Number of subjects: 20
Study: 27977568

Group type: EXPERIMENTAL
Intervention: Human patient simulator intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Teaching session attendance rates
Number of subjects: 191
Study: 25187119

Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg (N=703)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Placebo (N=351)
Number of subjects: 1054
Study: 24145806

Group type: EXPERIMENTAL
Intervention: Aintree technique via classic laryngeal mask airway (cLMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fastrach technique via intubating laryngeal mask airway (iLMA)
Number of subjects: 80
Study: 22045833

Group type: EXPERIMENTAL
Intervention: Continuous celecoxib 200 mg/day
Number of subjects: 858

Group type: COMPARATOR
Intervention: Intermittent celecoxib 200 mg/day
Number of subjects: 858
Study: 19553715

Group type: EXPERIMENTAL
Intervention: Universal Filtek Supreme XT + Flowable Filtek XT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Universal Filtek Supreme XT + Dyract Flow
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Filtek Z250 + Flowable Filtek XT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Filtek Z250 + Dyract Flow
Number of subjects: 72

Group type: COMPARATOR
Intervention: Universal Filtek Supreme XT
Number of subjects: 72

Group type: COMPARATOR
Intervention: Filtek Z250
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flowable compomer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LED light curing units (LCUs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: QTH light curing units (LCUs)
Number of subjects: 72
Study: 17216681

Group type: EXPERIMENTAL
Intervention: Women with prevalent vertebral fracture
Number of subjects: 3798

Group type: EXPERIMENTAL
Intervention: Women with at least 3 prevalent vertebral fractures
Number of subjects: 3798
Study: 15134769

Group type: EXPERIMENTAL
Intervention: Non-dominant view (embedded word)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects aware of the embedded word
Number of subjects: 0
Study: 11474724

Group type: EXPERIMENTAL
Intervention: Imagining committing social blunders (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiencing a public intellectual failure (Studies 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Being described in an embarrassing way (Study 4)
Number of subjects: 0
Study: 9562222

Group type: EXPERIMENTAL
Intervention: CPI123 (201.0±37.9W)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CPI135 (176.1±27.6W)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CPI345 (164.0±22.8W)
Number of subjects: 10
Study: 7881454

Group type: EXPERIMENTAL
Intervention: Bivariate random effects model for pharmacokinetic variables (AUC and CMAX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size formula
Number of subjects: 0
Study: 2905153

Group type: EXPERIMENTAL
Intervention: Azelastine 4.4 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31788985

Group type: EXPERIMENTAL
Intervention: Blonanserin (8-24 mg/d)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Risperidone (2-6 mg/d)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 302

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Blonanserin and Risperidone
Number of subjects: 302
Study: 30660443

Group type: EXPERIMENTAL
Intervention: CTY‐5339A (14% benzocaine/2% tetracaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 14% benzocaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CTY‐5339A
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CTY‐5339A and 14% benzocaine
Number of subjects: 50
Study: 28059603

Group type: EXPERIMENTAL
Intervention: Mastery Learning (ML) BLS course
Number of subjects: 43

Group type: COMPARATOR
Intervention: Time-Based (TB) BLS course
Number of subjects: 43
Study: 25782427

Group type: EXPERIMENTAL
Intervention: Vitamin K1 supplementation (1000 μm phylloquinone, one pearl softgel capsule daily for 4 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (one placebo capsule daily for 4 weeks)
Number of subjects: 82
Study: 23681143

Group type: EXPERIMENTAL
Intervention: Perioperative IV lidocaine (2 mg·kg·h)
Number of subjects: 116
Study: 21870317

Group type: EXPERIMENTAL
Intervention: VibroX (vibration exercise with superimposed resistance exercise and vascular occlusion)
Number of subjects: 21
Study: 19342294

Group type: EXPERIMENTAL
Intervention: Caffeine (200mg total; 100mg capsule three hours before and remaining dose one hour before daytime recovery sleep)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 17660909

Group type: EXPERIMENTAL
Intervention: Early-loaded ITI implants (loaded 6 weeks after surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventionally-loaded ITI implants (loaded 12 weeks after surgery)
Number of subjects: 50
Study: 15851312

Group type: EXPERIMENTAL
Intervention: Paced QRS duration (measured in ms)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Paced QRS duration
Number of subjects: 1026
Study: 12227482

Group type: EXPERIMENTAL
Intervention: Oral finasteride (1 mg per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of finasteride and topical minoxidil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical 2% minoxidil solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Finasteride with topical ketoconazole
Number of subjects: 100
Study: 9849288

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study: 8143406

Group type: EXPERIMENTAL
Intervention: Streamlined tip design enteroclysis tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corsafe tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanically assisted infusion of methylcellulose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other 10F enteroclysis tubes
Number of subjects: 0
Study: 2644531

Group type: EXPERIMENTAL
Intervention: sequential methotrexate and fluorouracil followed by leucovorin
Number of subjects: 679
Study: 1058091

Group type: EXPERIMENTAL
Intervention: Nuva Seal
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Epoxy‐Lite 9075
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (unsealed teeth)
Number of subjects: 104
Study: 29858517

Group type: EXPERIMENTAL
Intervention: Perineural injections
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intraneural injections
Number of subjects: 24